prefer cipla dr reddi among larg cap
upgrad cipla outperform review
prefer order larg cap sector posit
cipla dr reddi multipl re-rat trigger
stock posit lupin upsid requir clearanc
impact plant sun pharma near-term overhang flag
classif inspect halol expect current
month potenti price fix penalti us
busi front see improv us gener
market lower price eros domest formul market
key impedi stock high number advers
inspect howev cipla dr reddi alreadi wit
inspect key plant
pharma sector benefit sharp reduct crude
price benefit visibl near term solvent price
lower packag cost expect lower crude price
reflect lower api cost sector
sector attract current sever compani trade one
standard deviat histor price-to-earnings multipl
sun pharma multipl risk expect play view
stock overhang multipl risk potenti price fix penalti
taro link link multipl ranbaxi drug litig
link cautiou view ramp-up specialti drug ilumya cequa
pend flag classif halol plant
inspect view sensit quantit impact
risk could addit larg cash outgo
could also impact financi flexibl execut futur acquisit
key event stock halol plant flag classif expect
current month progress doj investig price fix
litig taro former taro execut arrest last
lipitor litig ranbaxi product may start
fact-discoveri complet three
month outcom
forens audit
financi busi front key factor sun pharma
ramp-up ilumya cequa restasi gener entri key event
extent market shift absorica new form far
pick-up approv halol facil
fact discoveri closur timelin within next
sebi
settlement worst case add rs dr
reddi china dr reddi among compani
file inject drug expect competit intens
oral drug inject could good opportun dr
reddi although larg benefit inject china
visibl contract win oral formul drug prior
could help market gaug potenti china opportun
cipla multipl re-rat trigger multipl trigger
specialti asset susten above-market growth india
grevlimid litig settlement like cipla new strategi
higher focu larg brand india lower focus
us limit exposur specialti segment find stock
attract profit india south africa sa
strong pipelin asset us stock trade
ep one standard deviat histor mean link
lupin upsid significantli depend facil clearanc lupin
multipl disappoint reduc visibl us launch
six eight
inhal lupin
solosec ramp-up slowa big drag profit
neg surpris cost despit cost reduct guidanc
result close grey scenario
valu india emerg market em
franchis
earn howev upsid function facil clearanc wherein
goa plant gavi plant clearanc may take year
near term us sale ramp-up driven market share gain
levothyroxin lupin tripl capac equival
market share current market share catalyst
approv benbrel gfostair eu
figur target price bridg lupin
figur impact potenti risk sun pharma
dr reddi option valu grevlimid settlement china
view stock still factor upsid
grevlimid settlement meaning opportun dr
reddi pre-trial confer date set
statu non-u analyst us disclosur credit suiss seek busi compani cover research report result investor
awar firm may conflict interest could affect object report investor consid report singl factor make invest
charl martineau pm univers toronto compani mention price
anubhav aggarw certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view
express report
price rate histori cipla limit cipl bo
signifi initi assumpt coverag
price rate histori dr reddi laboratori limit redi bo
signifi initi assumpt coverag
charl martineau pm univers toronto price rate histori lupin ltd lupn bo
signifi initi assumpt coverag
price rate histori sun pharmaceut industri limit sun bo
signifi initi assumpt coverag
decemb analyst stock rate defin follow
outperform stock total return expect outperform relev benchmark next month
neutral stock total return expect line relev benchmark next month
under-perform stock total return expect under-perform relev benchmark next month
relev benchmark region decemb japanes rate base stock total return rel analyst
coverag univers consist compani cover analyst within relev sector outperform repres
attract neutral less attract underperform least attract invest opportun octob
canadian well european exclud turkey rate base stock total return rel analyst coverag univers
consist compani cover analyst within relev sector outperform repres attract neutral less
attract underperform least attract invest opportun latin america turkey asia exclud japan australia
stock rate base stock total return rel averag total return relev countri region benchmark india
bse sensex index prior octob canadian rate base stock absolut total return potenti
current share price rel attract stock total return potenti within analyst coverag univers australian
new zealand stock expect total return calcul includ roll dividend yield outperform rate assign
greater equal under-perform less equal neutral may assign
overlap rate rang allow analyst assign rate put context associ risk
prior may rang outperform under-perform rate overlap neutral threshold
oper juli
restrict certain circumst credit suiss polici and/or applic law regul preclud certain type commun
includ invest recommend cours credit suiss engag invest bank transact certain
circumst
rate nr credit suiss equiti research invest rate view stock secur relat
compani time
cover nc credit suiss equiti research provid on-going coverag compani offer invest rate
invest view equiti secur compani relat product
volatil indic stock defin volatil stock price move month least
past month analyst expect signific volatil go forward
charl martineau pm univers toronto analyst sector weight distinct analyst stock rate base analyst expect fundament and/or
valuat sector rel group histor fundament and/or valuat
overweight analyst expect sector fundament and/or valuat favor next month
market weight analyst expect sector fundament and/or valuat neutral next month
underweight analyst expect sector fundament and/or valuat cautiou next month
analyst coverag sector consist compani cover analyst within relev sector analyst may cover multipl sector
credit suiss distribut stock rate bank client
purpos nyse finra rate distribut disclosur requir stock rate outperform neutral under-perform
